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Little research has been undertaken on risk factors for obesity in young people in Latin
America, including Mexico, despite the fact that obesity constitutes the number one
public health problem in Mexico. Our objective was to investigate the effect of the
Peroxisome proliferators-activated receptor (PPAR)_3 gene on BMI measured among
adolescents collected from a cohort study originally designed for epidemiological
studies.  METHODS: Blood samples and anthropometric measurements were collected
from 1,210 out of 13,294 public school students of both sexes, aged 11-24 years in
Morelos, Mexico. In this study, we genotyped 7 selected SNPs of the PPAR_ transcript
variant 3 (including Pro12Ala) in a group of unrelated 717 males and 493 females (age
range 11-24), including 3 SNPs located in the 5’ untranslated region.  These 7 SNPs
were selected by the tagging algorithm implemented in the program haploview to scan
the whole gene.  We tested each of the 7 SNPs individually for association with the
body mass index (BMI), and two SNPs (rs2938392 and rs1175542) revealed significant
associations with BMI (p-value=0.008 and 0.029, respectively). The SNP rs2938392 is
roughly 41.5 Kb from rs1801282 (Pro12Ala in PPAR_2).  Furthermore, we examined
the association between haplotypes built from 7 SNPs and BMI using a score statistic
implemented in the program haplo.stats.  While the permutation based global p-value
was 0.544, one individual haplotype with a frequency of 0.279 gave a p-value of 0.089
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(permutation based).  However, when the analyses were conducted in males only, the
permutation based global p-value was 0.055 and one individual haplotype with a
frequency of 0.28 gave a significant p-value of 0.013.
1. Introduction
The goal of this study was to investigate the effect of the Peroxisome
proliferators-activated receptor (PPAR)_3 gene on Body Mass Index (BMI)
measured among Mexican adolescents.  Although it has been established that
both PPAR_2 and PPAR_3 are expressed uniquely in colon and adipocyte
tissue and their potential role in the metabolic disorders such as obesity and
type 2 diabetes has been suggested [1], the reported effects of the Pro12Ala
polymorphism on susceptibility for obesity have been inconsistent [2]. The
detailed findings from all positive or negative studies are given in Table 1.
Table 1 A summary of Pro12Ala findings in different studies
Ref Sample size Ethnicity P-value
[3] 517 being lean-to-moderately obese Caucasian 0.01
[3] 169 very obese Caucasian <0.001
[4] 333 non-diabetic Scandinavian 0.027
[4] 973 non-diabetic Scandinavian 0.015
[5] 215 men Asian 0.65
[6] 296 extremely obese Caucasian >0.05
[6] 130 underweight Caucasian >0.05
[7] 752 obese Caucasian 0.008
[7] 869 non-obese Caucasian 0.005
[8] 141 obese Scandinavian 0.011
[9] 131 diabetic Caucasian 0.8
[9] 312 normoglycemic Caucasian 0.9
[10] 1025 diabetic Caucasian >0.05
[10] 310 with normal BMI Caucasian >0.05
[11] 108 non-diabetic Caucasian 0.67
[11] 19 overweight Caucasian 0.71
[12] 295 non-diabetic non-obese Caucasian >0.05
[12] 372 morbidly obese Caucasian >0.05
[12] 402  diabetic Caucasian >0.05
[13] 541 non-diabetic Asian 0.15
[13] 415 diabetic subjects Asian 0.10
[14] 165 obese Caucasian 0.017
[15] 229 Asian >0.05
[16] 921 Caucasian 0.011
[17] 476 Scandinavian 0.3
[18] 675 men Caucasian 0.64
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ID Sample size Ethnicity P-value
[19] 228 with normal BMI Scandinavian 0.070
[19] 217 with dyslipidemia Scandinavian 0.034
[19] 649 without dyslipidemia Scandinavian 0.080
[20] 280 with normal BMI Caucasian >0.05
[20] 95 obese Caucasian 0.32
[20]  42 young obese Caucasian <0.05
[21] 619 Caucasian 0.035
[22] 453 from 10 families Mexican >0.05
[23] 2201 diabetics Asian 0.881
[23] 1212 with normal BMI Asian 0.846
[24] 292 obese Caucasian 0.89
[24] 371 lean Caucasian 0.47
[25]  259 men Caucasian 0.554
[25] 333 women Caucasian 0.678
[26] 124 non-diabetics Caucasian 0.31
[27] 2245 non-diabetics Scandinavian >0.05
[28] 1107 diabetics Caucasian 0.3
[29] 438 Caucasian >0.05
[30] 478 men Asian >0.05
[30] 117 women Asian >0.05
[31] 145 obese Caucasian >0.05
[31] 317 non-obese Caucasian >0.05
[32] 210 monozygotic twins Scandinavian 0.09
[32] 344 dizygotic twins Scandinavian >0.05
[33] 720 Caucasian 0.005
[34] 253 with low physical activity level Caucasian >0.05
[34] 253 with high physical activity level Caucasian p<0.05
[35] 420 diabetic Asian 0.566
[35] 538 with impaired glucose tolerance Asian 0.875
[35] 3080 with normal BMI Asian 0.037
Few studies have investigated the association between PPAR_ gene and
BMI in the Mexican population. The most recent report was from Hsueh et al.
2001 [22], based on the study of 453 subjects comprising of 10 pedigrees.
However, no significant effect was found in their study.
While most of previous studies have focused on the effect of Pro12Ala or
PPAR_2, we have chosen to study PPAR_3, which contains the region of
PPAR_2, but also includes a 5’ untranslated region of the PPAR_ gene.
Interestingly, the expression of PPAR_3 is directed by an independent
promoter, and to date, at least three promoters in the upstream region of
PPAR_3 have been identified through molecular studies [1]. We analyzed seven
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tagging SNPs spanning 89.5kb of PPAR_3 gene region, and four of them were
located in the long 5’-end untranslated region. Our motivation is to examine the
effect of the haplotypes that represent the PPAR_3 genes, rather than focusing
on Pro12Ala itself.  
2. Methods
2.1. Study Population
This study builds on a parent cohort study carried out by Lazcano-Ponce et al.
(2003).  The parent study was the 1998-1999 baseline measurement of a cohort
study of 13,293 students at public junior high and high schools and a state
university in the central Mexican State of Morelos.  The Research Ethics
committee of the National Institute of Public Health approved the study
Protocol for epidemiological studies.  Further, The IRB review board of Johns
Hopkins Bloomberg School of Public Health approved the current study which
uses 1,270 anonymous DNA samples out of 13,293 Mexican students to test for
association between BMI and SNPs residing in the PPAR 3 gene.  Table 2
gives information on age and gender in this study population.
Table 2 Characteristics of the study group subjects
Variable Male Female Whole population
No. of Subjects 717 493 1210
Age 15.56±2.67 15.84±2.93 15.67±2.78
BMI 23.76±5.76 23.45±5.61 23.63±5.7
2.2. DNA extraction and Genotyping
DNA extraction was performed using the Gentra DNA extraction kit
following the manufacturer’s suggestion.  Out of 1,270 buffy coat samples,
1,210 samples gave sufficient DNA for this study. TaqMan, developed by
Applied Biosystems (ABI), is an efficient system and genotyping was
performed at the core genotyping facility at Johns Hopkins University.
The PCRs were conducted with both primers and probes added and only
end point products were read. The Hydra and Biomek FX was used to dispense
DNA samples and set up PCRs, respectively. The PCR was conducted in two
9700 thermocyclers each equipped with a dual 384-well blocks. Then the end
point products were scored using the 7900HT. In each 384-well plate, two
reference samples were included for quality control. The primers and probes were
designed using Primer Express (ABI). The probes were labeled with two
fluorescent dyes, one as an indicator and the other as a quencher.  Two probes
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were synthesized for each locus, each labeled with two different dyes as
indicators, respectively.
2.3. SNP tagging
We used the haploview program, http://www.broad.mit.edu/mpg/haploview/
[37] to compute the pair-wise LD measure D’. Haploview estimates the
maximum-likelihood values of the 4 gamete frequencies, from which D’ can be
calculated. For these calculations we included members of our melanoma
families as well as 350 individuals with BMI less than 25.  The SNP haplotype
tagging strategy (htSNP) allowed us to identify regions of strong LD using the
Gabriel et al block definition [38], and kept every inter-block SNP plus the
single SNP within each block with the highest minor allele frequency (MAF).
The LD structure of these 7 selected SNPs is presented in Figure 1.  The marker
rs1801282 represents Pro12Ala in PPAR_2.
Figure 1 LD structure of the selected SNPs in PPAR_3. The numbers within each block indicate the
pair –wise D’ as a percentage. The higher LD linkages are shown in the darker color, while the
first three SNPs constitute an LD block spanning 9kb of gene region. Moreover, all of these three
SNPs are located in the 5’-untranslated region of PPAR_3.
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2.4. Statistical analysis
Hardy-Weinberg proportions were tested among individuals with BMI less than
25 using the Pearson chi-square test. Pair-wise linkage disequilibrium was
evaluated by two linkage disequilibrium parameters, Lewontin’s D  [39] and r2
[40], which were both calculated in haploview (data not shown).
2.4.1. Single SNP analysis
Single SNP analyses were conducted using the linear regression procedure
implemented in STATA version 9. The SNP effects were analyzed using three
models which were, respectively: additive, dominant and recessive models. In
the additive model, the wild type genotype, the homozygote consisting of the
most common allele in the population, was treated as the baseline and coded as
1, while the heterozygote was coded as 2 and the other homozygote was coded
3. In the dominant model, the wild type homozygote was coded by 1 as
baseline and the heterozygote and the other homozygote were both coded 2.
Moreover, in the recessive model, both of the wild type homozygote and
heterozygote were treated as baseline with the rare homozygote coded 2.
2.4.2. Haplotype analysis
All haplotype frequencies were estimated using the expectation maximization
(EM) algorithm in haplo.stats in the R programming language
(http://mayoresearch.mayo.edu/mayo/research/biostat/schaid.cfm). Schaid et al
[41] developed a score statistic that can be used to test the statistical association
between haplotypes and different types of human traits, including binary and
quantitative traits. This method also allows adjustment for non-genetic factors.
In this analysis, we used haplo.stats to compute the global score statistic (which
allows us to test the significance of association considering all haplotypes) and
obtain a global p-value and the haplotype specific statistic (which allows us to
compare each haplotype with a selected common haplotype). All haplotypes
with a frequency less than 1% were dropped from the score test in order to
reduce the degrees of freedom. Another advantage of Schaid’s method is to
compute empirical p-values using simulation when the haplotype data is sparse.
The empirical p-values are computed by repeatedly first permuting the genotypes
among the subjects and then computing the score statistics.
3. Result
Hardy-Weinberg proportions were tested among individuals with BMI less than
25 using the Pearson chi-square test and no SNPs showed deviation from Hardy
Weinberg equilibrium.  The minor allele frequencies are 0.479, 0.130, 0.134,
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0.143, 0.445, 0.151 and 0.441 for SNPs rs17036314, rs12490265, rs4684847,
rs1801282, rs2938392, rs2959273, rs1175542, respectively.
Linear regression analysis of single SNP revealed two SNPs associated with
BMI with significant p-values reported in Table 3 (non-adjusted for multiple
testing).
Table 3. Significant associations revealed by single SNP analysis and
the body mass index (BMI)
SNP ID Location Population Model Coefficient P-value
rs2938392 Second intron Whole Dominant 1.0866 0.008
rs2938392 Second intron Male Dominant 1.3818 0.009
rs1175542 Fifth intron Whole Recessive 0.898 0.029
rs1175542 Fifth intron Male Recessive 1.171 0.029
In addition, we used a sliding window technique to fine map any potential
signals within the larger haplotype using haplo.stats [41]. The size of the
window varied from 3-4 SNPs in order to provide a comprehensive assessment
of the haplotype subsets within the gene. Permutation based p-values were
summarized in Table 4 for significant SNP combinations.
Table 4. Haplotypes revealing significant associations with BMI
using 1,210 Mexican samples, p-value(sim) indicated the p-values
based on permutation.
Haplotypes Frequency P-value P-value
(sim)
rs17036314*1/rs12490265*2/rs1801282*1 0.38952 0.05224 0.0495
rs17036314*1/rs4684847*1/rs1801282*1 0.38808 0.05637 0.058
rs17036314*2/rs2938392*1/rs1175542*2 0.28722 0.05607 0.0555
rs12490265*2 /rs1801282*1/ rs2938392*2 0.42052 0.05121 0.0512
rs12490265*2 /rs1801282*1/ rs1175542*1 0.42607 0.05451 0.0558
rs17036314*1/rs12490265*2/rs4684847*1/rs1801282*1 0.38607 0.03466 0.034
rs17036314*2/rs4684847*1/rs2938392*1/rs1175542*2 0.2869 0.05644 0.0564
rs12490265*2/rs4684847*1/rs1801282*1/ rs2938392*2 0.42129 0.0388 0.0387
rs12490265*2/rs4684847*1/rs1801282*1/ rs1175542*1 0.42648 0.04124 0.043
Furthermore, we examined the association between haplotypes built from 7
SNPs and BMI using a global score statistic.  While the permutation based
global p-value was 0.544 (degree of freedom=11), one individual haplotype gave
a p-value of 0.086 (permutation based) in all samples for a haplotype frequency
of 0.279.  Interestingly, when the analyses were conducted in males only, the
permutation based global p-value was 0.055, and one relatively frequent
haplotype (frequency =0.28) gave a significant signal of 0.013.
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3. Discussion
To summarize, we genotyped the 7 selected SNPs of the PPAR_ transcript
variant 3 (including pro12Ala) in a group of unrelated 717 males and 493
females (ages ranging from 11-24), among which 3 SNPs are located in the 5’
untranslated region.  These 7 SNPs were selected by the tagging algorithm
implemented in haploview to cover the whole gene and all SNPs conformed to
Hardy-Weinberg equilibrium.  We tested each of the 7 SNPs individually for
association with body mass index (BMI).  Although no association between
Pro12Ala and BMI was observed, two SNPs rs2938392 and rs1175542 revealed
significant associations with BMI (p-values=0.008 and 0.029, respectively). It
is worth noting that the SNP rs2938392 is roughly 41.5 Kb away from
Pro12Ala (rs1801282), a polymorphism known to be associated with BMI and
diabetes type II.  Furthermore, when all 7 SNPs were analyzed together, the
permutation based global p-value was 0.544, and one individual haplotype
(haplotype frequency =0.279) gave a significant signal of 0.086 (permutation
based).  Moreover, when the analyses were conducted in males only, the
permutation based global p-value was 0.055, and one relatively frequent
haplotype (frequency =0.28) gave a significant signal of 0.013.
Several speculations may explain our findings.
1. There is no association between Pro12Ala polymorphism and BMI in the
1,210 school students from Morelos, Mexico.  The positive signals we
detected are false positives, which may be due to the high-level admixture
structure in the Mexican population.  
2. There may not be a direct association between Pro12Ala and BMI, however,
SNPs which are in high LD with Pro12Ala are associated with BMI in
Mexican population, but this hypothesis will need to be further
investigated.  
3. Environmental factors may play a role to increase the genetic effect and the
lack of data on dietary factors and physical activities in this data set may
have limited the power to detect an association.
To summarize, our results indicate that SNPs in high linkage
disequilibrium with Pro12Ala are associated with BMI in 1,210 students in
Morelos, Mexico.  However, due to limited access to the epidemiological
factors such as dietary factors and physical activities, the results we reported here
need to be interpreted with caution.  Future study will explore causal
associations between other genetic and non-genetic risk factors and obesity in
this population.  Further studies will consider increased sample sizes, and we
will genotype 40 random SNPs to assess the level of population admixture this
population.
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